[News Release] An article about Satsuma Pharmaceuticals, Inc. in the United States was published in the Nikkei Sangyo Shimbun dated July 18.

An article about Satsuma Pharmaceuticals, Inc. (hereinafter referred to as "Satsuma", California) was published in the Nikkei Sangyo Shimbun dated July 18, 2019.
Satsuma Corporation is a company established in the United States in 2016 to develop a nasal migraine medication (nasal dihydroergotamine, hereinafter referred to as nasal DHE, development code: STS101) using our proprietary nasal technology as part of our translational research (TR) business.

The article introduces the clinical trial development status of intranasal DHE at Satsuma Corporation and our intranasal administration platform technology.

Our company will continue to contribute to the creation of new pharmaceuticals through the research and development of intranasal administration platform technology.

1) Nasal migraine medication
In the United States, the number of migraine patients has reached over 37 million, and the market size was reported to be approximately 180 billion yen as of 2017. This condition is characterized by its prevalence among relatively young working-age individuals in their 20s to 40s, and there is a strong demand for the development of medications that quickly alleviate the headaches that become a source of anxiety in daily life. Satsuma's developmental compound, DHE, is effective even for patients for whom triptan formulations, the first-line drugs, do not work. However, the commercially available DHE nasal spray (aqueous solution) has the issue of slow absorption, taking about 30 minutes for the effect to manifest, and the absorption of the drug tends to vary, making it difficult to achieve reliable clinical effects. Satsuma's STS101, in its Phase 1 clinical trial, demonstrated rapid and stable high absorption, which is expected to greatly meet market needs.